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In vivo [6,6-2H2]-glucose labeling is a state-of-the-art technique for quantifying cell 
proliferation and cell disappearance in humans. However, there are discrepancies 
between estimates of T cell proliferation reported in short (1-day) versus long (7-day) 
2H2-glucose studies and very-long (9-week) 2H2O studies. It has been suggested that 
these discrepancies arise from underestimation of true glucose exposure from intermit-
tent blood sampling in the 1-day study. Label availability in glucose studies is normally 
approximated by a “square pulse” (Sq pulse). Since the body glucose pool is small and 
turns over rapidly, the availability of labeled glucose can be subject to large fluctuations 
and the Sq pulse approximation may be very inaccurate. Here, we model the pharma-
cokinetics of exogenous labeled glucose using a physiologically based pharmacokinetic 
(PBPK) model to assess the impact of a more complete description of label availability as 
a function of time on estimates of CD4+ and CD8+ T cell proliferation and disappearance. 
The model enabled us to predict the exposure to labeled glucose during the fasting and 
de-labeling phases, to capture the fluctuations of labeled glucose availability caused by 
the intake of food or high-glucose beverages, and to recalculate the proliferation and 
death rates of immune cells. The PBPK model was used to reanalyze experimental data 
from three previously published studies using different labeling protocols. Although using 
the PBPK enrichment profile decreased the 1-day proliferation estimates by about 4 and 
7% for CD4 and CD8+ T cells, respectively, differences with the 7-day and 9-week stud-
ies remained significant. We conclude that the approximations underlying the “square 
pulse” approach—recently suggested as the most plausible hypothesis—only explain a 
component of the discrepancy in published T cell proliferation rate estimates.
Keywords: deuterium labeling, T cell kinetics, cell turnover, mathematical modeling, systems biology
inTrODUcTiOn
Reliable estimates of lymphocyte turnover are important to understand the immune response in 
health and disease. Until recently, concerns about the potential toxicity of labels, such as BrdU (1), 
[3H]-thymidine (2), or CFSE (3), restricted labeling experiments to in vitro and animal studies (4–6). 
This problem was overcome with the introduction of stable isotope-labeling techniques (7, 8), which 
have the advantage of being non-toxic at tracer doses (9) and are suitable for use in humans. Both 
[6,6-2H2]-glucose (2H2-glucose) (7) and heavy water (2H2O) (8) have been used to measure in vivo 
cell turnover. Glucose enters nucleoside biosynthesis through the pentose phosphate pathway, los-
ing one carbon (C1) to form the pentose ring on which purine and pyrimidine nucleosides are 
FigUre 1 | illustration of the “square pulse” approach. (a) Label availability during the labeling period in 2H2-glucose studies is estimated from the area under 
the curve of plasma label enrichment during the labeling period (typically based on 6–8 measurements). Areas of the trapezoids a–f are summed to obtain the area 
(light blue shading) representing the average enrichment during the labeling time. An adjustment (dark blue-shaded area, “g”) to account for the de-labeling tail is 
calculated from the last enrichment data point, glucose pool size, and glucose disappearance to adjust for label availability during the delabelling phase and is 
added to the mean enrichment (20). (B) Label availability is then represented by a “square pulse” whose area is equal to the light blue- plus dark blue-shaded area 
during the labeling period, which returns to 0 once label administration ends.
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subsequently synthesized (7); heavy water contributes deuterium 
moieties in place of hydrogen at several sites across the nucleoside 
molecule (10). Labeled nucleotides are then incorporated into 
newly synthesized DNA, generating labeled DNA. Since both are 
used at tracer doses, it is assumed that the underlying physiology 
is not perturbed. Significant human applications of this technique 
include the study of T cell (11–13), B cell (14, 15), granulocyte (7, 
16), NK cell (17), and monocyte (8, 11) dynamics.
Despite the success of this approach, there are considerable 
discrepancies in the estimates of T cell proliferation reported in 
2H2-glucose studies using 1-day labeling compared with 7-day 
labeling (18, 19). After a series of in vitro, in vivo, and in silico 
studies it was suggested that an underestimation of the 2H2-
glucose enrichment in the 1-day labeling study may have caused 
an overestimation of the proliferation rates and thus explain the 
discrepancy (19). 2H2-glucose studies normally describe label 
availability as an “square pulse” (Sq pulse) (Figure 1) (20). The 
“square pulse” approximation might be reasonable in the case 
of primed and long intravenous infusions where carbohydrate 
(CHO) intake is limited. However, it may break down when 
protocols allow large CHO intake, which will cause fluctuations 
in label availability. In addition, an unbalanced distribution of 
measurements over postprandial and fasting stages could either 
under- or overestimate the mean exposure to label. Finally, it 
has been assumed that the “tail” of residual 2H2-glucose during 
delabelling can be accounted for by increasing the amount of 
label exposure during the labeling phase. Although this may 
adequately reflect the total level of label exposure, it will change 
the timing of label availability (Figure  1). This limitation will 
become more important for shorter labeling periods, when the 
tail makes a proportionately greater contribution and when the 
glycogenesis rate is increased by meal intake (2H2-glucose may be 
accrued in glycogen and released at later time points).
In this study, we implement a physiologically based pharma-
cokinetic (PBPK) model to simulate glucose labeling experiments 
for IV protocols by extending an existing model of the glucose–
insulin–glucagon regulatory system (21). This model allows using 
full label enrichment versus time profiles for the interpretation of 
labeling experiments, i.e., profiles representing the label enrich-
ment fluctuations during meal intake, account for higher enrich-
ments during the night (when samples are normally not taken), 
and the tail after glucose infusion. We evaluated the performance 
of our model by post hoc in silico predictions of labeled plasma 
glucose in human studies. Next, we used our PBPK simulations of 
label availability to recalculate CD4+ and CD8+ T cell prolifera-
tion and disappearance (i.e., due to phenotype change, migration 
to non-measureable tissues, or death) rates from existing studies 
in order to test whether this recalculation would resolve the 
disparity in turnover estimates.
MaTerials anD MeThODs
Datasets
Blood plasma 2H2-glucose enrichment data from three previ-
ously published stable isotope-labeling studies were analyzed 
(11, 12, 22). Label enrichment in the DNA from T cells was also 
reported in two of the studies [a 1-day 2H2-glucose (12) and a 
7-day 2H2-glucose (11)] and used for T cell proliferation and dis-
appearance rate estimation. Only data from healthy individuals 
were used.
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Tigas et al. Study
In the study of Tigas et  al. (22), 2H2-glucose was administered 
in combination with [1-13C]-glucose to six healthy young men 
(average age 28 ± 2 years, BMI 23.7 ± 1.2 kg/m2). Only mean data 
were reported (Table S1 in Supplementary Material). Infusion 
rates were constant (prime dose 5.95  mg/kg; infusion rate 
0.1  mg/kg⋅min for both 2H2-glucose and [1-13C]-glucose). 
Infusion times of 2H2-glucose were 2.5  h (protocols A and B), 
5 h (protocol C), and 14.5 h (protocol D), starting at time 0 h. A 
co-infusion of [1-13C]-glucose of 2.5 h in protocols A, C, and D 
(co-infusion start times were 0, 2.5, and 12 h, respectively) and 
14.5 h in protocol B (starting time–12 h) was administered. An 
IV bolus of glucagon was administered 3 h after infusions were 
concluded. Subjects were fasted throughout the experimental 
period. Plasma enrichment during the last 30 min of the infusions 
and during the subsequent 4  h was measured. Priming doses, 
infusion doses, and infusion times are available in Table S2 in 
Supplementary Material.
Macallan et al. (1-Day Labeling) Study
Macallan et  al. (12) administered a primed IV infusion of 
approximately 1 g/kg 2H2-glucose to eight healthy subjects (four 
males, four females) over a period of approximately 24 h; exact 
dose/times varied but were recorded (see Tables S3 and S4 in 
Supplementary Material for specific anthropometric data and 
dosing scheme, respectively). Subjects received up to six meals 
during the infusion time (see Tables S5 and S6 in Supplementary 
Material for details in meal intakes).
Mohri et al. (7-Day Labeling) Study
Mohri et al. (11) administered a primed IV infusion of 30 g/day 
of labeled glucose for 7 days to four healthy controls (two males, 
two females). During the labeling period, subjects received a 
very-low CHO diet (<46 g/day). Anthropometric data, priming 
dose, and meal intake times were not recorded. Sampling was 
performed after an overnight fasting.
Interpretation of T Cell DNA Labeling Data
In the 1-day 2H2-glucose study (12), both CD8+ and CD8− CD3+ 
T cell populations were sorted into naïve (defined as CD45RA+) 
and memory (CD45RA−) subpopulations before analysis (12). In 
the 7-day 2H2-glucose study, total CD4+ and CD8+ CD3+ T cell 
populations were sorted and analyzed (11). To compare T cell data 
from the two studies therefore, naïve and memory T cell data from 
the 1-day 2H2-glucose study were combined, weighting the enrich-
ment of each subpopulation according to the relative sizes of the 
CD45RA+ and CD45RA− blood pools, to obtain an enrichment 
value equivalent to that of a combined total CD8+ and CD8−  
population. For consistency with prior published studies (12, 19, 23), 
we refer to CD8− T cells as CD4+ T cells.
Models
2H2-Glucose PBPK Model
A PBPK model of the glucose–insulin–glucagon regulatory 
system recently published by Schaller et  al. (21) was extended 
to account for labeled glucose in addition to unlabeled glucose 
(Figure S1 in Supplementary Material). A PBPK model is based 
on an organism-specific parameter set and a compound-specific 
parameter set (24, 25). The original PBPK model combined three 
basic PBPK models of glucose, insulin, and glucagon, coupled by 
pharmacokinetic and pharmacodynamic (PK/PD) interactions: 
liver glucose metabolism, pancreas insulin/glucagon secretion, 
fat/muscle GLUT4 insulin-mediated active uptake, and the gut 
incretin effect. Here, we extend the model to account for the 
PK/PD processes of labeled glucose in the form of 2H2-glucose 
(MW  =  182.17  g/mol). We assume (i) PK/PD properties of 
glucose and 2H2-glucose are the same—normal glucose and 2H2-
glucose compete for all active transports (i.e., GLUT2, GLUT3, 
GLUT4, and SGLT-1), cellular metabolism, renal excretion, and 
glycogen synthesis in a proportion-dependent manner. In addi-
tion, the influence of glucose and 2H2-glucose on hepatic glucose 
uptake, hepatic glucose production, and insulin and glucagon 
secretion are additive; (ii) glucose, 2H2-glucose, glucagon, 
and insulin PK/PD properties are the same for all individuals; 
(iii) in muscle and fat cells, glucose is metabolized by glycogenesis 
and triglyceride synthesis (26), these glucose sinks are implicitly 
represented in the model by setting the redistribution of glucose 
from muscle and fat cells back to the interstitial space to 0; 
(iv) meals are ingested for 10 min, i.e., each meal is modeled as 
an oral glucose uptake with a duration of 10 min (see Figure S4 in 
Supplementary Material for further details and impact of assuming 
different ingestion times); (v) glucose from meals is released instan-
taneously; (vi) hepatic glycogen (i.e., normal unlabeled glycogen) 
concentrations are fixed at a mean physiological value [450 mmol/ml 
wet tissue (27)]; and (vii) label recycling via glycogenesis/
glycogenolysis is assumed to have an efficiency of 40%, i.e., 40% 
of the deuterium label is recycled within the glycogenesis/
glycogenolysis cycle (see Text S2 in Supplementary Material 
and Figure S5 in Supplementary Material for further details and 
impact of assuming different recycling efficiencies). To examine 
the performance of the 2H2-glucose PBPK model, we simulated 
previously published studies that used 2H2-glucose as a tracer/
labeling compound and measured the label enrichment in plasma 
during labeling phase and/or delabelling phase. The model was 
implemented using the Computational Systems Biology Software 
Suite (28) (Bayer AG, Leverkusen, Germany; www.systems-
biology.com) version 5.4.2 (PK-Sim 5.4.2 version, MoBi 3.4.2 
version). This software is available with version 7.0.0 under the 
name Open Systems Pharmacology Suite at the GitHub reposi-
tory www.open-systems-pharmacology.org. 2H2-glucose model 
fits were conducted using the MoBi Toolbox for R and the FME 
package in R statistical software version 2.15.3 (29, 30).
Simulations of the Tigas et al. Study
Subject weight, height, sex, ethnicity, and gender were used to 
generate a PBPK parameterization characteristic of the average 
adult volunteer of Tigas et al.’s study (Table S1 in Supplementary 
Material). Since we were not interested in analyzing the 
[1-13C]-glucose enrichment, the [1-13C]-glucose was modeled 
as normal glucose. Protocols A and B had identical 2H2-glucose 
infusion rates and time, and results were conflated in the original 
publication. Protocols A, C, and D were simulated by using the 
administration times, prime doses, and infusion rates reported 
by Tigas et al.
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Simulations for the Macallan et al. (1-Day Labeling) Study
Subject weight, height, sex, ethnicity, and gender were used to 
generate a PBPK parameterization characteristic of each subject 
(Table S3 in Supplementary Material). The model was further 
individualized by including infusion time, prime, and infused 
dose for each subject reported by Macallan et al. (12) (Table S4 
in Supplementary Material). Food intake was extracted from 
record sheets and the CHO content of each meal estimated 
either from dietary labeling or published nutritional information 
(31, 32) (Tables S5 and S6 in Supplementary Material). Since no 
data were available for food intake after the end of the labeling 
period, we estimated CHO intake assuming three daily meals for 
5 days after the labeling period, together providing a daily CHO 
intake equivalent to that of the “average” British citizen (237 g/day) 
(33). CHO intake was modeled as an oral administration of diluted 
glucose (see model assumptions). Energy content, meal volume, 
and fraction solid were used to define the meal effects on the 
gastric emptying time (34, 35). Simulations of the 1-day labeling 
experiments were optimized by fitting the CHO of meal intake 
for the individuals for whom a considerable deviation between 
model predictions of plasma enrichment and experimental data 
was observed (Figure S2 in Supplementary Material) during 
postprandial phases. Since there was uncertainty in measure-
ments on both the ordinate (enrichment) and the abscissa (time) 
axes, orthogonal least squares between simulation and observa-
tion were used as the penalty function. The vector of the residual 
orthogonal distance was calculated as follows (Eq. 1):
 
ROD min= −( ) + −( )




( ) ( )
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2 2

 
(1)
where n is the number of observations, d subscript stands for 
data and s subscript stands for simulated vector of values. For 
error normalization, both the abscise and the ordinate axes were 
standardized by subtracting the mean and by dividing by the SD 
of the measured times and enrichments, respectively. The best fit 
CHO content is provided in Table S8 in Supplementary Material.
Simulations for the Mohri et al. (7-Day Labeling) Study
A primed IV infusion of 30 g/day of labeled glucose was mod-
eled for 7 days. The prime dose was as assumed to be 6.6% of 
the daily dose, as in other protocols (12). CHO intake (45 g/day) 
was split into three different meals (breakfast, lunch, and dinner). 
Anthropometric data were not available for the study of Mohri 
et  al.; we, therefore, estimated the weight and height by fitting 
the simulation to the observed plasma enrichment (11). Meal 
intake after labeling was modeled as in the 1-day 2H2-glucose 
experiment.
Kinetic Heterogeneity (kh) Model of T Cell Kinetics
The kh model (36) is used to estimate cell proliferation and 
disappearance from labeling studies. The kh model considers a 
population of constant size that proliferates at a rate “p,” which 
is representative of the whole population. Labeled cells are lost 
(due to phenotype change, migration to non-measureable tissues, 
or death) at a rate “d*” (36), which is representative of the labeled 
population of cells only.
In order to fit the model to the DNA fractional enrichment, 
it is necessary to normalize by the maximum fraction of label 
attainable (65%) in cellular DNA “b” (7, 20) and the plasma 
glucose enrichment (Ut) assuming a rapid equilibration of 2H2-
glucose between plasma, proliferation site, and the intracellular 
space of T cells. The model is as follows (Eq. 2):
 
dA
dt
b p A U d At
∗
∗ ∗= ⋅ ⋅ ⋅ − ⋅
 
(2)
where A is the total amount of deoxyadenosine in a cell popula-
tion and A* is the amount of labeled deoxyadenosine. Equation 2 
can be rewritten by dividing by the total deoxyadenosine amount 
(36), yielding the following:
 
dX
dt
b p U d Xt
∗
∗ ∗= ⋅ ⋅ − ⋅
 
(3)
where X* is the fraction of labeled deoxyadenosine of cells in the 
proliferation sites (X* = A*/A). This model was used to analyze 
the datasets from 1-day 2H2-glucose (12) and 7-day 2H2-glucose 
(11) labeling experiments. In the case when we used the glucose 
PBPK simulations Ut in Eq. 3, above was given by the plasma 2H2-
glucose PBPK simulations shown in the results section. When 
using the “square pulse” approach, Ut was calculated as described 
in Figure  1. Finally, for consistency with previous published 
experiments (11), we included a lag time to represent the delay of 
cells leaving the proliferation sites (e.g., lymphoid tissue) for the 
peripheral blood where they are detected, following Mohri et al. 
(11); this lag time was fixed to half-a-day, we also allowed cell 
death during the lag time (Eq. 4).
 L t X t lag e
lag d∗ ∗ ∗( ) = −( ) ⋅ − ⋅  (4)
where L* is the fraction of labeled deoxyadenosine of cells in 
peripheral blood (the observed variable). Data from each indi-
vidual were fitted separately using the pseudorandom algorithm 
in the FME package in R (29, 30, 37).
relationship between administered Dose 
and Fasting Plasma enrichment
A linear regression to explain the relationship between infusion 
rate and plasma enrichment was performed. Only samples taken 
during fasting periods were considered.
label exposure required in the glucose 
1-Day study for agreement with the 
glucose 7-Day and Water 9-Week labeling 
studies
The kh model was fitted to the CD4+ and CD8+ data of each 
individual simultaneously with the area under the curve (AUC) 
of the “square pulse” and loss rate as free parameters, while fixing 
the proliferation rate of each subpopulation to the median values 
estimated from analyzing the 7-day study dataset.
FigUre 2 | comparison of predictions of plasma 2h2-glucose enrichment to experimental data during and after 2h2-glucose iV infusion. Tigas et al. 
protocols A, C, and D (one graph per protocol) (22). During each protocol, six fasting individuals received both 2H2-glucose and [1-13C]-glucose intravenous infusions 
for varying times with an injection of glucagon at time +3 h post end-of-infusion. Blue circles represent all the experimental data available in the Tigas et al. 
publication (data were reported as the mean of six individuals); solid line represents the model prediction.
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statistical analyses
Differences were compared using the two-tailed Wilcoxon 
Signed Rank Sum test for paired data (i.e., when comparing 
parameter estimates found using two methods of estimating 
2H2-glucose plasma enrichment applied to the same dataset) and 
the Mann–Whitney test for unpaired data (i.e., when comparing 
parameter estimates from different datasets) unless otherwise 
stated. All reported p values are uncorrected and two-tailed.
resUlTs
2h2-glucose PBPK Model
The 2H2-glucose PBPK model is an extension of a previously pub-
lished model of the glucose–insulin–glucagon regulatory system 
(21). The glucose–insulin–glucagon metabolism model we used 
consists of four basic PBPK models for the molecules 2H2-glucose, 
glucose, insulin, and glucagon, coupled by pharmacodynamic 
interactions (Figure S1 in Supplementary Material).
Model Performace: Post Hoc Predictions of a 2H2-
Glucose IV Infusion Protocol
We first assessed model performance by simulating an independ-
ent study performed by Tigas et  al. (22). Post hoc predictions 
of 2H2-glucose plasma enrichments were compared with the 
experimental data. Importantly, no model parameters were fitted 
at this step.
The 2H2-glucose enrichments of protocols A, C, and D 
of the Tigas et  al.’s study (22) were simulated using the 
PBPK model, taking into account the administration of 
2H2-glucose, [1-13C]-glucose, and glucagon and using the 
priming doses, infusion doses, and infusion times reported 
by Tigas et  al. (Table S2 in Supplementary Material). Model 
predictions described experimental data well (Figure  2), the 
only exception being that following the glucagon IV bolus 
the decrease in enrichment in the simulations is smaller than 
the experimentally observed effect. This is to be expected as 
the PBPK model was not developed for non-physiological 
concentrations of glucagon [glucagon plasma concentrations 
are >2,000  pg/ml after dosing (22)] and cannot, therefore, 
describe the impact of high-dose exogenous glucagon accurately.
Simulation of 2H2-Glucose Plasma Enrichment during 
Deuterium Labeling Studies
Next, we simulated the 2H2-glucose plasma enrichment for the 
studies that triggered our original research question (11, 12). 
Macallan et  al. (12) administered 2H2-glucose during 1  day to 
eight healthy individuals. In contrast to Tigas et al.’s study, indi-
viduals were not fasted. Anthropometric characteristics for each 
individual, priming dose, infusion dose, and infusion times were 
set to the reported values (see Tables S3 and S4 in Supplementary 
Material). The PBPK model predictions of 2H2-glucose enrich-
ment were in good agreement with experimental data during 
fasting; however, agreement was poorer during the first 4  h of 
infusion and postabsorptive stages (Figure S2 in Supplementary 
Material). In order to obtain a better description of the after-meal 
label fluctuations, the CHO content of meals was fitted in the 
cases where there was a large discrepancy between prediction and 
observation as described in the Section “Materials and Methods” 
(Figure  3, individuals C02–C10; Table S8 in Supplementary 
Material).
In the study by Mohri et  al. (11), a 2H2-glucose IV primed 
infusion was administered to four healthy controls for 7 days, 
label enrichment in plasma was measured after an overnight 
fast while consuming a very-low CHO diet throughout the 
labeling study. Anthropometric data were not recorded, so 
we estimated the weight and height of the four individuals by 
fitting the simulated fasting enrichment to the data of Mohri 
et  al. (11). Estimates are in the physiological range (Table S9 
in Supplementary Material). Results are shown in Figure  3, 
individuals C1–C4. The mean relative AUC increase compared 
to the “square pulse” estimation was +9.8% for the 1-day study: 
20% (C02), 2% (C03), 1% (C04), 4% (C05), 17% (C06), 13% 
(C07), 8% (C08), 13% (C10); and −2.5% for the 7-day study: −2 
(C1), −4 (C2), −2 (C3), and −2 (C4).
FigUre 3 | 2h2-glucose plasma enrichment simulation of the deuterium labeling studies used to estimate T cell proliferation rates. Macallan et al. 
(upper eight graphs) dataset (12): each of the eight subjects (C02–C10) received a primed 2H2-glucose intravenous infusion for approximately 24 h and ingested up 
to six (unlabeled) meals. Mohri et al. (lower four graphs) dataset (11): each individual (C1–C4) received a 2H2-glucose primed IV infusion of 30 g/day for 7-day, 
carbohydrate (CHO) intake was restricted to <46 g/day. Blue circles represent the experimental data, red vertical lines indicate meal intakes during the labeling 
period, blue vertical lines (C06 plot) represent ingestion of high-glucose beverages (e.g., fruit juice), triangles indicate meals for which CHO content was fitted, and 
black line represents model prediction.
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analysis of T cell stable isotope-labeling 
Data
It has been hypothesized that use of the “square pulse” approach 
(20) might have led to biased estimates of proliferation rates 
between the 1-day and 7-day 2H2-glucose studies described above 
due to unbalanced sampling between postabsorptive and fasting 
stages and/or changes in the timing of label availability, i.e., the 
delabelling tail (19). We aimed to address this question by using 
PBPK model simulations as an input to a T cell turnover model 
to recalculate cellular proliferation and death.
Comparison of the estimates obtained by the conventional 
approach (“square pulse”) and the PBPK simulations showed a 
statistically significant, but numerically small, decrease in the 
proliferation of CD8+ T cells (mean relative change −7%; p < 0.05, 
two-tailed Wilcoxon Signed-Rank Sum test), but not in CD4+ 
T cells estimates (Figure 4). On the other hand, disappearance rates 
significantly increased (mean relative changes 13 and 5% for CD4+ 
and CD8+ T  cell populations, respectively; p <  0.05, two-tailed 
Wilcoxon Signed-Rank Sum test; Figure 4). For the 7-day labeling 
experiment, plasma 2H2-glucose PBPK input slightly increased 
both proliferation rates and disappearance rates of both subpopula-
tions but differences were not significant at the subpopulation level 
(p > 0.12, two-tailed Wilcoxon Signed-Rank Sum test). Model fits 
are shown in Figure S3 in Supplementary Material.
Despite using a more accurate representation of label availabil-
ity differences in proliferation rate, estimates between the 1-day 
and the 7-day 2H2-glucose studies remained significant (two-
tailed Mann–Whitney test, Figure  5). Differences between the 
FigUre 4 | comparison T cell proliferation and disappearance rate estimates obtained for the 1-day labeling experiment dataset using “square 
pulse” and physiologically based pharmacokinetic (PBPK) simulations. Plasma label enrichment was represented either by a “square pulse”  (Sq pulse) or by 
PBPK model simulation (PBPK Sim). A kinetic heterogeneity (kh) model describing T cell dynamics (36) was then fitted to labeling data from CD4+ and CD8+ T cells 
in eight individuals labeled with deuterated glucose for 1 day (see Figure S3 in Supplementary Material for model fits). The resulting estimates of the proliferation rate 
and disappearance rate of the T cell subsets are represented above. Significance levels: *p < 0.05; nsp > 0.05, two-tailed Wilcoxon Signed-Rank Sum test.
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2H2-glucose 7-day and the 2H2O 9-week labeling study remained 
non-significant (19, 23).
PBPK Model-Free analysis of Plasma 
2h2-glucose enrichment
Another observation that supported the hypothesis that deute-
rium enrichment in the 1-day study had been underestimated 
has been reported (19). It was noticed that in the 1-day study, 
despite administering twice as much glucose as in the 7-day 
study, the measured plasma enrichments did not differ twofold 
(19). This was interpreted as a potential underestimation of the 
precursor availability (19).
We investigated this observation by taking into account the 
nutritional stage of each measurement (i.e., postabsorptive, 
FigUre 6 | effect of infusion rate on experimentally measured 
enrichment during fasting. Data are from Tigas et al. (22) (circles), Mohri 
et al. –7-day labeling– (11) (triangles), and Macallan et al. –1-day labeling– 
(20) (squares). The solid line is the best fitting straight line through the data; 
the shaded gray area represents the 95% confidence interval of the mean of 
the fasting enrichment given a specific infusion rate predicted by the linear 
model. Pearson product–moment correlation between fasting enrichment 
and infusion rate is r = 0.97, p < 0.001 (16 data points).
FigUre 5 | comparison of proliferation estimates for the 2h2-glucose 1-day (12), 2h2-glucose 7-day (11), and 9-week 2h2O (23) labeling experiment 
datasets. 2H2-glucose enrichment input for the kh model (36) was represented by the “square pulse” (Sq pulse) or by PBPK model simulation (PBPK Sim). The kh 
model was then fitted to 2H2-glucose 1-day and 7-day labeling data from CD4+ and CD8+ T cells (see Figure S3 in Supplementary Material for model fits). CD4+ 
proliferation rates from the 9-week 2H2O (D2O) labeling experiment were extracted from Westera et al. (23) and included for comparison; reconstruction for CD8+ 
cells from the 9-week 2H2O labeling study was not possible due to sorting methodology, discussed in Ref. (19). Significance levels: **p < 0.01; *p < 0.05; ns, 
non-significant; two-tailed Mann–Whitney test for unpaired data, two-tailed Wilcoxon Signed-Rank Sum test for paired data. Dots represent individual data, the 
box-plot represents the median, and inter-quartile range and whiskers represent the maximum and minimum values—excluding outliers.
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postprandial, or fasting). In the 7-day study, all measurements 
were taken after fasting; therefore, in order to be comparable 
only fasting enrichments from the 1-day labeling study should be 
considered. On doing this, we found a strong linear correlation 
between deuterium administration and deuterium enrichment 
in plasma (Figure 6), consistent with similar rate constants for 
glucose disposal (Rd)—in the 1-day study, ~8.00 g/h; in the 7-day 
study, ~7.12 g/h. Bearing in mind the additional 1–2 g/h given in 
the former, endogenous glucose disposal rates are almost identi-
cal, showing that the glucose enrichment estimates are consistent 
between the two studies. The differences in glucose enrichments 
may thus be attributed to the differences in meal intake, indicat-
ing that the previous conclusion was distorted by not taking into 
account the differences between postabsorptive and fasting stages 
in the 1-day study.
label exposure required in the glucose 
1-Day study for agreement with the 
glucose 7-Day and Water 9-Week labeling 
studies
Finally, we assessed how much label availability in the 1-day 
labeling study would need to increase in order to produce T cell 
turnover rates in agreement with the 7-day study. We found that 
label availability would need to be three times higher (Table 1) 
than previously estimated. Such a large error seems unlikely 
and further supports the conclusion that discrepancies are not 
entirely caused by the approximations of the “square pulse” 
approach.
DiscUssiOn
Deuterium labeling is an essential technique for quantifying 
in vivo immune cell turnover in health and disease. We hypoth-
esized that discrepancies in published estimates (18, 19) may 
arise from underestimation of labeled glucose availability when 
TaBle 1 | label exposure required (fitted sq Pulse) in the glucose 
1-day study (12) in order to solve the discrepancies with the 7-day (11) 
and water 9-week (13) labeling studies, compared to original “square 
pulse” (sq pulse) exposure and exposure from physiologically based 
pharmacokinetic simulations (PBPK sim).
area under the curve (%·day)
sq pulse PBPK sim fitted sq Pulse
C02 20.13 24.11 79.55
C03 27.42 28.04 61.85
C04 27.04 27.19 53.84
C05 26.50 27.44 71.94
C06 18.91 22.07 95.68
C07 24.43 27.69 99.99
C08 25.04 26.96 51.92
C10 25.64 28.96 99.99
Mean 24.39 26.56 76.85
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intermittent sampling is combined with discontinuous feeding. 
Possible mechanisms include: (i) an inappropriate balance of 
measurements between postprandial and fasting stages, (ii) 
rapid fluctuations in label availability after meal intake, and/
or (iii) inaccuracy in estimating the contribution from the 
delabelling curve (19). In order to address these issues, we used 
a PBPK model to estimate glucose label availability throughout 
the labeling and delabelling period; and then used this descrip-
tion of precursor availability to re-estimate CD4+ and CD8+ 
T cell proliferation and disappearance rates. The direction of 
the change in proliferation rates in both the 1-day and the 7-day 
labeling study is consistent with previous predictions obtained 
using an independent method (estimation of monocyte plateau 
DNA enrichment) (19). Our refined estimates of T cell turno-
ver rates suggest a life span of 104 and 109 days for CD4+ and 
CD8+ T cells, respectively, if estimated from the 1-day labeling 
study data, compared to 210 and 341 days for CD4+ and CD8+ 
T  cells, respectively, using the 7-day data. The differences 
between turnover rates estimated using the “square pulse” 
approach and the PBPK profiles are numerically small (−4 and 
−7%, for CD4+ and CD8+ data, respectively, 1-day labeling 
study) and thus only partially resolve the discrepancies in T cell 
proliferation rate estimates between 1-day and 7-day studies. 
Interestingly, estimates of the rate of disappearance of CD4+ 
and CD8+ T cells increased when calculated using the PBPK 
enrichment profiles, suggesting that previously published rates 
were underestimates.
This work demonstrates the power of PBPK modeling to 
integrate known physiological and biological parameters. Using 
this approach, we were able to include variability in meal intakes 
and the effect of a delabelling tail for two published 2H2-glucose 
labeling studies (a 1-day labeling protocol and a 7-day labeling 
protocol). There are, however, two main limitations. First, in 
previous work in type1 Diabetes mellitus, individual param-
eterization of the PBPK model (including fractional glomerular 
filtration rates of insulin and glucagon, sensitivities to insulin 
and glucagon, and the catalytic rate constant of SGLT1) was ten-
able (21). In the present study, by contrast, data were scarce and 
we, therefore, used parameterization of the model representative 
of the mean healthy population. Second, the uncertainty regard-
ing meal intake parameters (i.e., CHO content, meal volume, 
composition, and ingestion time) could have led to the errors 
during postprandial phases seen in some individuals in the origi-
nal PBPK predictions (Figure S2 in Supplementary Material), 
although other factors not included in the model (e.g., glycemic 
index, meal protein/fat proportion, intra-occasional variability) 
may also play a role (21). 2H2-glucose plasma simulations were 
taken as the input term to estimate cell kinetics using a T cell 
turnover model that assumed kinetic heterogeneity (36); this is 
a low parameter approximation of a multi-compartment model 
which (provided the populations are not saturated) yields the 
same average proliferation rate as the multi-compartment model 
without the problem of overfitting. We tested other phenom-
enological models of T cell turnover and found that differences 
between T cell turnover estimates from 1 day and 7 day labeling 
were still significant (Text S1 in Supplementary Material). This 
suggested that differences are not a particular artifact of the 
T cell turnover model used.
In summary, the results presented here show that discrepan-
cies are not entirely caused by the approximations of the “square 
pulse” approach, although it may result in an overestimation of 
proliferation rates of about 4 and 7% for CD4 and CD8+ T cells, 
respectively, in short labeling studies. Going forward, difficul-
ties in estimating label availability may be minimized in future 
studies by limiting the CHO content of meals to reduce label 
fluctuations, as was done in the 7-day labeling study, and by more 
frequent plasma sampling during and after label administration, 
especially during short labeling protocols. Why the 1-day 2H2-
glucose, 7-day 2H2-glucose, and 9-week 2H2O studies yield differ-
ent estimates of T cell turnover is still not completely explained. 
Alternative explanations might be sought by the application of 
physiologically based models of T  cell proliferation, including 
trafficking between blood (i.e., sampling site) and non-blood 
(i.e., proliferating sites) compartments.
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